The CHMP concluded in its review that the benefits no longer outweigh the risks and that they could not identify additional measures that would reduce the cardiovascular risk.
- Prescribers should put into place a system to review all patients currently prescribed Avandia or Avandamet, and change them to another suitable treatment in line with NICE recommendations. (See MIMS summary of NICE guidance on type 2 diabetes)
- This change can occur at the next routine appointment or prescribers may wish to see patients sooner rather than later to reduce patient anxiety.
- Patients taking rosiglitazone-containing medicines should consult their doctor about alternative treatment.
- Patients should not stop taking Avandia or Avandamet without consulting their doctor.